Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multi-Center, Dose Escalation, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3068 in Adult Patients With Advanced Solid Tumors

Trial Profile

A Phase 1, Multi-Center, Dose Escalation, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3068 in Adult Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2018

At a glance

  • Drugs JAB-3068 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Jacobio Pharmaceuticals
  • Most Recent Events

    • 15 May 2018 Planned End Date changed from 30 Apr 2020 to 1 Apr 2020.
    • 15 May 2018 Planned primary completion date changed from 30 Nov 2019 to 1 Nov 2019.
    • 15 May 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top